- Report
- February 2026
- 104 Pages
Global
From €4520EUR$4,900USD£3,791GBP
- Report
- February 2026
- 128 Pages
Global
From €4520EUR$4,900USD£3,791GBP
- Report
- October 2025
- 100 Pages
Global
From €4520EUR$4,900USD£3,791GBP
- Report
- June 2026
- 143 Pages
Global
From €3689EUR$3,999USD£3,094GBP
- Report
- June 2026
- 142 Pages
Global
From €3689EUR$3,999USD£3,094GBP
- Report
- May 2026
- 142 Pages
Global
From €3689EUR$3,999USD£3,094GBP
- Report
- May 2026
- 143 Pages
Global
From €3689EUR$3,999USD£3,094GBP
- Report
- May 2026
- 137 Pages
Global
From €3689EUR$3,999USD£3,094GBP
- Report
- April 2026
- 144 Pages
Global
From €3689EUR$3,999USD£3,094GBP
- Report
- April 2026
- 150 Pages
Global
From €3689EUR$3,999USD£3,094GBP
- Report
- April 2026
- 139 Pages
Global
From €3689EUR$3,999USD£3,094GBP
- Report
- April 2026
- 144 Pages
Global
From €3689EUR$3,999USD£3,094GBP
- Report
- April 2026
- 144 Pages
Global
From €3689EUR$3,999USD£3,094GBP
- Report
- April 2026
- 141 Pages
Global
From €3689EUR$3,999USD£3,094GBP
- Report
- April 2026
- 145 Pages
Global
From €3689EUR$3,999USD£3,094GBP
- Report
- April 2026
- 135 Pages
Global
From €3689EUR$3,999USD£3,094GBP
- Report
- April 2026
- 150 Pages
Global
From €3689EUR$3,999USD£3,094GBP
- Report
- April 2026
- 143 Pages
Global
From €3689EUR$3,999USD£3,094GBP
- Report
- February 2026
- 143 Pages
Global
From €3689EUR$3,999USD£3,094GBP
- Report
- September 2026
- 315 Pages
Global
From €2306EUR$2,500USD£1,934GBP

The biologic market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs. Biologic drugs are made from living organisms, such as proteins, nucleic acids, and cells, and are used to treat a variety of diseases. These drugs are typically more complex and expensive to produce than traditional small-molecule drugs. The biologic market is highly competitive, with many companies vying for market share.
The biologic market is divided into two main segments: therapeutic biologics and biosimilars. Therapeutic biologics are drugs that are developed to treat a specific disease or condition, while biosimilars are drugs that are similar to existing biologic drugs but are not identical.
Some of the major players in the biologic market include Amgen, Biogen, Celgene, Gilead Sciences, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. These companies are involved in the development, production, and marketing of biologic drugs. Show Less Read more